according to europeanpharmaceuticalreview
Game-changing immunotherapy doubles head and neck cancer survival
Game-changing immunotherapy doubles head and neck cancer survival
You are here: Home » News » Industry news » 'Game-changing' immunotherapy doubles head and neck cancer survival10 October 2016 • Author: Niamh Louise Marriott, Digital Content ProducerAn immunotherapy drug has been hailed as a potential 'game changer' after being found to greatly improve survival for patients with relapsed head and neck cancer – a disease which is notoriously difficult to treat.Nivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed – and it did so with fewer side-effects than existing therapeutic options.More than double the number of patients taking nivolumab were alive after one year as those treated with chemotherapy, reported the major international trial.There are currently no other treatment options that improve the survival of patients with cisplatin-resistant relapsed or metastatic head and neck cancers.
coupled with irishexaminer
Drug offers hope to neck and head cancer sufferers
Drug offers hope to neck and head cancer sufferers
New immunotherapy treatment twice as effective as chemotherapy against aggressive form of cancerAn immunotherapy drug could soon offer hope to patients with currently untreatable head and neck cancers.Nivolumab was hailed a potential game-changer after it was found to extend the lives of relapsed patients who had run out of therapy options.After a year of treatment, 36% of trial patients treated with the drug were still alive compared with 17% of those given standard chemotherapy.READ NEXT Former Rose of Tralee Maria Walsh: Being young, female entrepreneur can be hardPatients with advanced head and neck cancers resistant to chemotherapy are notoriously difficult to treat and generally survive less than six months.
additionally onmedica
Drug could double head and neck cancer survival
Drug could double head and neck cancer survival
Drug could double head and neck cancer survivalTrial suggests immunotherapy drugs prolongs survivalAdrian O'Dowd Monday, 10 October 2016An immunotherapy drug appears to greatly improve survival for patients with relapsed head and neck cancer – a disease known to be difficult to treat – according to a study* published at the weekend in The New England Journal of Medicine.An international team of researchers has described the drug nivolumab as a potential "game changer" following their major international trial.Currently, there are no other treatment options that improve the survival of patients with cisplatin-resistant relapsed or metastatic head and neck cancers and these patients are expected to live less than six months.The trial was led in the UK by Professor Kevin Harrington of The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 20 research organisations from around the world.
moreover from eurekalert
'Game-changing' immunotherapy doubles head and neck cancer survival
'Game-changing' immunotherapy doubles head and neck cancer survival
An immunotherapy drug has been hailed as a potential 'game changer' after being found to greatly improve survival for patients with relapsed head and neck cancer - a disease which is notoriously difficult to treat.Nivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed - and it did so with fewer side-effects than existing therapeutic options.More than double the number of patients taking nivolumab were alive after one year as those treated with chemotherapy, reported the major international trial, published today (Sunday) in the New England Journal of Medicine.There are currently no other treatment options that improve the survival of patients with cisplatin-resistant relapsed or metastatic head and neck cancers.
No comments:
Post a Comment